Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 24, 2025, titled "Glenmark Strengthens Oncology Portfolio with Hengrui s HER2 Targeting ADC For Multiple Regions".
Press Release Sep 24 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
- Press Release Sep 05 2025
- Press Release Sep 02 2025
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- FY 2024-25
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Oct 23 2025
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
- Glenmark Pharmaceuticals Limited Press Release Nov 04 2025
- Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
- Press Release Nov 10 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals